Claims
- 1. A method of treating carcinoma in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
3
- 2. The method of claim 1 wherein R is alkyl of from 1 to 4 carbons, n is 1, X is oxygen and the chloro is in the 3 position of the carbamate phenyl group.
- 3. The method of claim 1 wherein from 2 mg/kg to 1000 mg/kg body weight is administered.
- 4. The method of claim 1 wherein said N-chlorophenylcarbamate, N-chlorophenylthiocarbamate, or salt thereof is administered orally, enterically, intravenously, parenterally, or by injection.
- 5. A method of treating ovarian carcinoma in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
4
- 6. A method of treating carcinoma in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a combination of
a chemotherapeutic agent, and an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
5 wherein
n is from 1 to 3, X is selected from the group consisting of oxygen and sulfur; and R is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl; or a salt thereof.
- 7. The method of claim 6 wherein from 2 mg/kg to 1,000 mg/kg body weight of said N-chlorophenylcarbamate, N-chlorophenylthiocarbamate, or salt is administered, and from 0.5 mg/kg to about 400 mg/kg body weight of said chemotherapeutic agent is administered.
- 8. The method of claim 6 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, asparaginase, and hydroxyurea.
- 9. The method of claim 6 wherein said chemotherapeutic agent is selected from the group consisting of taxol, cisplatin, cyclophosphamide, altretamine, bleomycin, dactinomycin, doxorubicin, etoposide, teniposide and picamydin.
- 10. The method of claim 6 wherein said chemotherapeutic agent is selected from the group consisting of methotrexate, fluorouracil, fluorodeoxyuridine, CB3717, azacitidine, cytarabine, floxuridine, mercaptopurine, 6-thioguanine, fludarabine, pentostatin, cyctrabine, and fludarabine.
- 11. The method of claim 6 wherein the combination further comprises a potentiator.
- 12. A method of treating ovarian carcinoma in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a combination of
a chemotherapeutic agent, and an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
6 wherein
n is from 1 to 3, X is selected from the group consisting of oxygen and sulfur; and R is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl; or a salt thereof.
- 13. A method for treating a subject exposed to or infected with a retrovirus, comprising: administering to the subject a therapeutically effective amount of
an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
7 wherein
n is from 1 to 3, X is selected from the group consisting of oxygen and sulfur; and R is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl; or a salt thereof, to inhibit or prevent replication of said retrovirus in a cell of monocytic lineage of the subject.
- 14. The method of claim 13 wherein R is alkyl of from 1 to 4 carbons, n is 1, X is oxygen and the chloro is in the 3 position of the carbamate phenyl group.
- 15. The method of claim 13 wherein from 2 mg/kg to 1,000 mg/kg body weight is administered.
- 16. The method of claim 13 wherein said N-chlorophenylcarbamate, N-chlorophenylthiocarbamate, or salt thereof is administered orally, enterically, intravenously, parenterally, or by injection.
- 17. A method for treating a subject exposed to or infected with a retrovirus, comprising: administering to the subject a therapeutically effective amount of a combination of
a potentiator, and an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
8 wherein
n is from 1 to 3, X is selected from the group consisting of oxygen and sulfur; and R is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl; or a salt thereof, to inhibit or prevent replication of said retrovirus in a cell of monocytic lineage of the subject.
- 18. The method of claim 17 wherein R is alkyl of from 1 to 4 carbons, n is 1, X is oxygen and the chloro is in the 3 position of the carbamate phenyl group.
- 19. The method of claim 17 wherein from 2 mg/kg to 1,000 mg/kg body weight is administered.
- 20. The method of claim 17 wherein the potentiator enhances the effect of the N-chlorophenylcarbamate, N-chlorophenylthiocarbamate, or salt thereof.
- 21. The method of claim 17 wherein the potentiator is an immunomodulator.
- 22. The method of claim 20 wherein the potentiator is procodazole.
- 23. A method for treating a subject exposed to or infected with HIV retrovirus, comprising: administering to the subject a therapeutically effective amount of
an N-chlorophenylcarbamate or an N-chlorophenylthiocarbamate of the formula:
9 wherein
n is from 1 to 3, X is selected from the group consisting of oxygen and sulfur; and R is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, and phenyl; or a salt thereof, to inhibit or prevent replication of said HIV retrovirus in a cell of monocytic lineage of the subject.
Parent Case Info
[0001] The present application is a divisional of U.S. Ser. No. 09/364,021, filed Jul. 30 1999 which is a divisional of Ser. No. 08/876,705 filed Jun. 16, 1997, now U.S. Ser. No. 5,932,609 which is a divisional of U.S. Ser. No. 08/680,468 filed on Jul. 15, 1996 now U.S. Ser. No. 5,932,604. The patent and patent applications are incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60001888 |
Aug 1995 |
US |
Divisions (2)
|
Number |
Date |
Country |
Parent |
08876705 |
Jun 1997 |
US |
Child |
09364021 |
Jul 1999 |
US |
Parent |
08680468 |
Jul 1996 |
US |
Child |
08876705 |
Jun 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09408664 |
Sep 1999 |
US |
Child |
09748652 |
Dec 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09364021 |
Jul 1999 |
US |
Child |
09408664 |
Sep 1999 |
US |